Page 50 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine PI3K and Akt in androgen-independent PCa

doi: 10.1186/s12943-023-01827-6 doi: 10.1530/ERC-12-0394
9. Wang R, Qu Z, Lv Y, et al. Important roles of PI3K/AKT 19. Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role
signaling pathway and relevant inhibitors in prostate cancer of PTEN in regulating castration-resistant prostate cancer
progression. Cancer Med. 2024;13(21):e70354. growth. Cancer Cell. 2011;19(6):792-804.
doi: 10.1002/cam4.70354 doi: 10.1016/j.ccr.2011.05.006
10. Chen CY, Chen J, He L, Stiles BL. PTEN: Tumor suppressor 20. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal
and metabolic regulator. Front Endocrinol (Lausanne). feedback regulation of PI3K and androgen receptor
2018;9:338. signaling in PTEN-deficient prostate cancer. Cancer Cell.
2011;19(5):575-586.
doi: 10.3389/fendo.2018.00338
doi: 10.1016/j.ccr.2011.04.008
11. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role
of PI3K signaling in survival and progression of LNCaP 21. Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in
prostate cancer cells to the androgen refractory state. prostate cancer progression and androgen deprivation
Endocrinology. 2001;142(11):4795-4805. therapy resistance. Asian J Androl. 2014;16(3):378-386.
doi: 10.1210/endo.142.11.8467 doi: 10.4103/1008-682X.122876
12. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical 22. Liang F, Yue J, Wang J, et al. GPCR48/LGR4 promotes
demonstration of phospho-akt in high Gleason grade tumorigenesis of prostate cancer via PI3K/Akt signaling
prostate cancer. Clin Cancer Res. 2002;8(4):1168-1171. pathway. Med Oncol. 2015;32(3):49.
13. Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K- doi: 10.1007s12032-015-0486-1
AKT-mTOR pathway as a pro-survival signaling and 23. Lu Q, Liu Z, Li Z, et al. TIPE2 overexpression suppresses
resistance-mediating mechanism to therapy of prostate the proliferation, migration, and invasion in prostate cancer
cancer. Int J Mol Sci. 2021;22(20):11088.
cells by inhibiting PI3K/Akt signaling pathway. Oncol Res.
doi: 10.3390/ijms222011088 2016;24(5):305-313.
14. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, doi: 10.3727/096504016X14666990347437
version 3.2012: featured updates to the NCCN guidelines. 24. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-
J Natl Compr Canc Netw. 2012;10(9):1081-1087.
induced apoptosis by phosphorylating and inhibiting androgen
doi: 10.6004/jnccn.2012.0114 receptor. Proc Natl Acad Sci U S A. 2001;98(13):7200-7205.
15. Aurilio G, Cimadamore A, Mazzucchelli R, et al. Androgen doi: 10.1073/pnas.121173298
receptor signaling pathway in prostate cancer: From genetics 25. Manin M, Baron S, Goossens K, et al. Androgen receptor
to clinical applications. Cells. 2020;9(12):2653.
expression is regulated by the phosphoinositide 3-kinase/
doi: 10.3390/cells 9122653 Akt pathway in normal and tumoral epithelial cells. Biochem
J. 2002;366(Pt 3):729-736.
16. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms
of resistance in castration-resistant prostate cancer (CRPC). doi: 10.1042/BJ20020585
Transl Androl Urol. 2015;4(3):365-380.
26. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol
doi: 10.3978/j.issn.2223-4683.2015.05.02 3-kinase/Akt stimulates androgen pathway through
GSK3beta inhibition and nuclear beta-catenin accumulation.
17. Huang Y, Jiang X, Liang X, Jiang G. Molecular and cellular
mechanisms of castration resistant prostate cancer. Oncol J Biol Chem. 2002;277(34):30935-30941.
Lett. 2018;15(5):6063-6076. doi: 10.1074/jbc.M201919200
doi: 10.3892/ol.2018.8123 27. Ehsani M, David FO, Baniahmad A. Androgen receptor-
dependent mechanisms mediating drug resistance in
18. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR
pathway in castration-resistant prostate cancer. Endocr Relat prostate cancer. Cancers (Basel). 2021;13(7):1534.
Cancer. 2013;20(3):R83-R99. doi: 10.3390/cancers13071534

Volume 3 Issue 3 (2025) 42 doi: 10.36922/ARNM025160018